Even though patients with prostate cancer have improved overall survival, from a global perspective, this is a disease that requires attention in terms of better diagnostic and treatment modalities, especially at critical decision points and in the metastatic setting. Properly used prostate cancer tissue-based biomarkers can significantly improve prognostic determinations, risk stratification, and treatment selection.